A liquid crystal composition which prevents production of an alignment defect of a liquid crystal compound and also has excellent storage stability during dissolution in a solvent is provided. The liquid crystal composition is suitable for constituting a retardation film capable of favorable circular polarization conversion. The liquid crystal composition includes a polymerizable liquid crystal compound having 3 or more ring structures in the main chain, and aluminum. A content of the aluminum is 1 ppm or more and 170 ppm or less relative to the polymerizable liquid crystal compound.
A liquid crystal composition containing a polymerizable liquid crystal compound (A) having 5 or more ring structures in its main chain and a polymer (B) of the polymerizable liquid crystal compound (A) having 5 or more ring structures in its main chain, which inhibits occurrence of an orientation defect of a liquid crystal compound and exhibits excellent storage stability when dissolved in a solvent is provided.
Liquid crystal composition, method of producing the same, and retardation film constituted from the same
申请人:Sumitomo Chemical Company, Limited
公开号:US11193065B2
公开(公告)日:2021-12-07
A liquid crystal composition is provided containing a polymerizable liquid crystal compound, the composition having high preservation stability when dissolved in a solvent and also having the ability to restrain the development of orientation defects of the liquid crystal compound. A method of producing such a liquid crystal composition is also provided with ease. The liquid crystal composition includes a first polymerizable liquid crystal compound having five or more ring structures on its principal chain and represented by the following formula (A) and a second polymerizable liquid crystal compound having five or more ring structures and represented by the following formula (B).
MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20170096429A1
公开(公告)日:2017-04-06
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME
申请人:Sumitomo Chemical Company, Limited
公开号:US20170306234A1
公开(公告)日:2017-10-26
A liquid crystal composition is provided containing a polymerizable liquid crystal compound, the composition having high preservation stability when dissolved in a solvent and also having the ability to restrain the development of orientation defects of the liquid crystal compound. A method of producing such a liquid crystal composition is also provided with ease. The liquid crystal composition includes a first polymerizable liquid crystal compound having five or more ring structures on its principal chain and represented by the following formula (A) and a second polymerizable liquid crystal compound having five or more ring structures and represented by the following formula (B).